1. Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial. (February 2020) Authors: Yuen, Man-Fung; Agarwal, Kosh; Gane, Edward J; Schwabe, Christian; Ahn, Sang Hoon; Kim, Dong Joon; Lim, Young-Suk; Cheng, Wendy; Sievert, William; Visvanathan, Kumar; Ruby, Eric; Liaw, Sandy; Yan, Ran; Huang, Qi; Colonno, Richard; Lopatin, Uri Journal: Lancet gastroenterology and hepatology Issue: Volume 5:Number 2(2020) Page Start: 152 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗